Docket Room.
SF 4189·MN·senate

Commissioner of health direction to study and report on activities to support innovations in cell and gene therapy to treat rare diseases

FailedFiled Mar 5, 2026
Sponsor: Coleman
Latest Action

Author added

Apr 7, 2026

Email me when SF 4189 moves

Committee action, floor votes, amendments and hearings. Free, no card, no password.

Already have an account? Track SF 4189. By continuing you agree to the Terms and Privacy Policy.

Summary

The bill directs the state commissioner of health to conduct a comprehensive study of Minnesota’s capacity and strategies for cell and gene therapies that treat rare diseases. It requires a detailed report with recommendations to be delivered to the legislature by Jan. 1, 2028, and provides a one‑time appropriation for the work. The measure aims to inform policy, funding and regulatory actions that could improve access and economic development in this emerging field.

AI-generated summary — may be incomplete or inaccurate. Verify against the official bill text.

Ask about SF 4189

3 free questions a day, no account

History

  1. Author added Miller
  2. Author added Hemmingsen-Jaeger
  3. Author added Rasmusson
  4. Referred to Health and Human Services
  5. Introduction and first reading

Sponsors

  • Coleman · sponsor
  • Boldon
  • Hemmingsen-Jaeger
  • Miller
  • Rasmusson

Bill text

Read the official text ↗

Opens the legislature’s own copy.

Similar bills in other states

Loading the map of where bills like this one were filed.

Share

Writing about this bill? Add a live status widget to your site or newsletter. It updates as the bill moves.

Track this bill

Get an email when SF 4189 moves: committee action, floor votes, amendments and hearings. Free, no card.

Track SF 4189 free

Or ask your AI assistant about SF 4189 directly:

Add to Claude, ChatGPT or Cursor
Docket Room · Nonpartisan legislative tracking
Docket Room IntelligencePro

Ask about your legislation

I can analyze your tracked bills, upcoming hearings, and recent changes.

AI-generated · Nonpartisan · Not legal advice